Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Gilead Sciences has taken a major step towards increasing ... paving the way for increased production and distribution of lenacapavir, its long-acting HIV prevention medication, in 120 high ...

Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD patients challenged with rhinovirus.  In this study, ...

Gilead Sciences adds $11B to its U.S. investment plan, boosting manufacturing, R&D, and job creation. Read more here.